|Bid||79.70 x 100|
|Ask||81.04 x 100|
|Day's Range||79.40 - 80.90|
|52 Week Range||63.76 - 89.54|
|PE Ratio (TTM)||22.72|
|Forward Dividend & Yield||2.28 (2.79%)|
|1y Target Est||N/A|
Grants Awarded to 13 Canadian Initiatives to Help Advance the Goal of Eliminating Chronic Hepatitis C Infection in High-Risk Populations
Gilead Sciences, Inc. announced today that Norbert Bischofberger, PhD, has decided to step down from his role as Executive Vice President, Research and Development and Chief Scientific Officer, effective at the end of April 2018.
Gilead Sciences, Inc. today announced 48-week results from a Phase 3 study of 470 virologically suppressed adult women with HIV infection, evaluating the efficacy and safety of switching from a boosted protease inhibitor or boosted elvitegravir-containing regimen to Biktarvy® , a once-daily single tablet regimen.
Gilead Sciences, Inc. today announced detailed 48-week results from a Phase 3 study evaluating the efficacy and safety of switching from a regimen containing abacavir, dolutegravir and lamivudine to Biktarvy® , a once-daily single tablet regimen, in virologically suppressed adults with HIV.
Gilead Sciences, Inc. today announced results from a preclinical study conducted in collaboration with researchers at Beth Israel Deaconess Medical Center evaluating the combination of a proprietary investigational oral toll-like receptor 7 agonist, GS-9620, and a proprietary investigational broadly neutralizing antibody , PGT121, as part of an HIV eradication strategy.
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / U.S. markets closed lower Wednesday to end February in the red, with the Dow Jones and S&P 500 breaking its longest monthly gain streak since 1959. The Dow Jones ...
Gilead Sciences, Inc. announced today that James Meyers, Executive Vice President, Commercial Operations, will retire. Mr. Meyers joined Gilead in 1996 as a regional sales director and was appointed to his current role in 2016.
-- Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology -- SANTA MONICA, Calif. and RICHMOND, Calif. , Feb. 22, ...
Kite, a Gilead Company and Sangamo Therapeutics, Inc. today announced the companies have entered into a worldwide collaboration using Sangamo’s zinc finger nuclease technology platform for the development of next-generation ex vivo cell therapies in oncology.
LONDON, UK / ACCESSWIRE / February 21, 2018 / Active-Investors.com has just released a free research report on Gilead Sciences, Inc. (NASDAQ: GILD ) ("Gilead"). If you want access to this report ...
NEW YORK, NY / ACCESSWIRE / February 15, 2018 / U.S. markets rallied sharply from early losses Wednesday as inflation fears appear to be easing on Wall Street. The Dow Jones Industrial Average jumped 1.03 ...
NEW YORK, NY / ACCESSWIRE / February 12, 2018 / U.S. markets managed to finish in the green on Friday, despite concerns of rising interest rates and inflationary pressure. The Dow Jones Industrial Average ...
Gilead Sciences, Inc. today announced that Norbert W. Bischofberger, PhD, Gilead’s Executive Vice President, R&D and Chief Scientific Officer, and Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the RBC Capital Markets 2018 Global Healthcare Conference in New York on Wednesday, February 21 at 9:00 a.m.
Stock Monitor: Gilead Sciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 08, 2018 / Active-Investors.com has just released a free research report on Actinium Pharma, Inc. (NYSE: ATNM ). ...
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved Biktarvy® , a once-daily single tablet regimen for the treatment of HIV-1 infection.
Gilead Sciences, Inc. today announced that the company’s Board of Directors has declared an increase of 10% in the company’s quarterly cash dividend, beginning in the first quarter of 2018.
Gilead Sciences, Inc. announced today its results of operations for the fourth quarter and full year 2017. Total revenues for the fourth quarter of 2017 were $5.9 billion compared to $7.3 billion for the same period in 2016.
NEW YORK, NY / ACCESSWIRE / February 6, 2018 / Gilead Sciences, Inc. (NASDAQ: GILD ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 6, 2018 at 4:30 PM Eastern ...
Gilead Sciences, Inc. announced today that Jacqueline K. Barton, Ph.D., has been appointed to the company’s Board of Directors. She previously served on Gilead’s Scientific Advisory Board from 1989 to 2007.
NEW YORK, Feb. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alexander's, ...
Gilead Sciences, Inc. announced today that its fourth quarter and full year 2017 financial results will be released on Tuesday, February 6, after the market closes. At 4:30 p.m.
Kite, a Gilead Company , announced it has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the investigational combination of Yescarta™ and Pfizer's utomilumab, a fully humanized 4-1BB agonist monoclonal antibody, in patients with refractory large B-cell lymphoma.
CAR T and cell therapies are the next big wave of biomedical innovation and are set to become a multi-billion dollar industry in the next decade. One leader, Kite Pharma, was acquired for $12 billion months ...